SOM Biotech Announces the Database Lock of Its Phase IIb Study with SOM3355 in Huntington’s Chorea Patients and Looks for Top-Line Results in August
SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary artificial intelligence (AI) platform, is pleased to announce the database lock of the Phase IIb study...